A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia. Southwest Oncology Group Study. - Karanes,C.; Kopecky,K.J.; Head,D.R.; Grever,M.R.; Hynes,H.E.; Kraut,E.H.; Vial,R.H.; Lichtin,A.; Nand,S.; Samlowski,W.E.; Appelbaum,F.R. (Leuk Res, 1999)